Search
Gilead Sciences Inc
GILDAdd to Watchlist
130.840USD
+0.500+0.38%
Close 07-23 16:00（ET）Quotes delayed by 15 min
162.50BMarket Cap
17.65P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Gilead Sciences Inc is 8.19, ranking 51 out of 155 in the Pharmaceuticals industry. The average price target is 135.00, with a high of 153.00 and a low of 105.00.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
158.089
Target Price
+21.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Gilead Sciences Inc
GILD
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Gilead Sciences Inc's expected revenue for the next quarter?
Gilead Sciences Inc's expected revenue is 7.40B.
What is Gilead Sciences Inc's price target?
Analysts forecast that Gilead Sciences Inc's price target is USD 135.00, with the highest forecast at USD 153.00 and the lowest forecast at USD 105.00.
How have Gilead Sciences IncGILD's recent earnings per share performed?
The market expectation was USD 1.63, while Gilead Sciences IncGILD's earnings per share (EPS) for the previous quarter was USD 6.84. EPS for the next quarter is expected at USD -7.26.
What is the analyst rating for Gilead Sciences Inc?
Based on the ratings of Gilead Sciences Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.